Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study.

Area of Science:

• Hematology
• Oncology
• Platelet Physiology

Background:

• Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
• Platelet dysfunction is a recognized complication in MDS, impacting patient outcomes.
• Assessing platelet function is crucial for managing bleeding risks in MDS patients.

Purpose of the Study:

• To evaluate platelet function in patients with myelodysplastic syndromes.
• To correlate platelet aggregation and dense granule release with clinical bleeding and thrombosis.
• To determine the utility of whole-blood platelet aggregation studies in identifying bleeding risk.

Main Methods:

• Whole-blood platelet lumi-aggregometry was used for simultaneous measurement of platelet aggregation and adenosine triphosphate-dense granule release.
• Platelet function results were correlated with skin bleeding times.
• Clinical bleeding episodes and thrombotic events were recorded and analyzed.

Main Results:

• Most patients (35/48) exhibited platelet hypoactivity; only 2 had normal results.
• Platelet hypoactivity correlated with prolonged skin bleeding time, but aggregation studies were more sensitive.
• Clinical hemorrhage was frequent (32 patients) despite adequate platelet counts, highlighting functional importance.

Conclusions:

• Platelet dysfunction is prevalent in myelodysplastic syndromes and clinically significant.
• Whole-blood platelet aggregation studies are valuable for identifying patients at risk of bleeding.
• Platelet hyperactivity appears less critical for thrombosis in MDS compared to other factors.